Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMVMQ1L)

Drug Name
Nafronyl Drug Info
Synonyms
Nafronyl oxalate; 3200-06-4; Naftidrofuryl oxalate; Nafronyl oxalate salt; 2-(Diethylamino)ethyl 3-(naphthalen-1-yl)-2-((tetrahydrofuran-2-yl)methyl)propanoate oxalate; Naftidrofuryl (oxalate); Dusodril; Dubimax; Praxilene; Iridus; LS-121; EU-1806; DSSTox_RID_80935; DSSTox_CID_25533; DSSTox_GSID_45533; naftidrofuryl hydrogen oxalate; CHEMBL1439099; alpha-[1-Naphthylmethyl]-2-tetrahydrofuranpropionic acid diethylaminoethyl ester; SMR000539007; Nafronyl oxalate salt, analytical standard; CAS-3200-06-4; NSC225233; LS 121
Cross-matching ID
PubChem CID
4417
ChEBI ID
CHEMBL1620794
CAS Number
CAS 31329-57-4
TTD Drug ID
D07YWY
INTEDE Drug ID
DR2473

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
GABAergic synapse -1.64 4.90e-2 76/89 (85.39%) GNG4;SLC6A1;ADCY2;...
NF-kappa B signaling pathway -1.64 4.93e-2 90/104 (86.54%) CFLAR;BLNK;TICAM1;...
Neutrophil extracellular trap formation -1.68 4.15e-2 101/189 (53.44%) SIGLEC9;NFKB1;TLR8;...
Chemical carcinogenesis -1.68 3.99e-2 186/281 (66.19%) KLF4;MAPK1;CYP3A5;...
Fructose and mannose metabolism -1.69 4.24e-2 30/33 (90.91%) HK3;PFKP;ALDOB;...
B cell receptor signaling pathway -1.70 4.24e-2 71/81 (87.65%) NFATC1;PPP3CC;BLNK;...
Other glycan degradation -1.73 3.95e-2 13/18 (72.22%) MAN2B2;HEXA;GLB1;...
T cell receptor signaling pathway -1.73 4.26e-2 93/104 (89.42%) CD8A;CD40LG;IKBKB;...
Glycolysis / Gluconeogenesis -1.74 4.03e-2 56/67 (83.58%) PGK1;GPI;ALDH3B1;...
PD-L1 expression and PD-1 checkpoint pathway in cancer -1.75 3.90e-2 79/89 (88.76%) NRAS;TICAM1;MAP2K3;...
Th17 cell differentiation -1.76 4.01e-2 95/107 (88.79%) NFKBIB;STAT5A;HLA-DOB;...
Lysosome -1.76 4.00e-2 115/128 (89.84%) AP1S1;SLC11A1;GGA3;...
Proximal tubule bicarbonate reclamation -1.78 3.46e-2 21/23 (91.3%) ATP1B2;GLS;ATP1B3;...
Hematopoietic cell lineage -1.78 3.95e-2 90/99 (90.91%) HLA-DOB;CSF2RA;CD8A;...
Primary bile acid biosynthesis -1.89 1.38e-2 15/17 (88.24%) BAAT;CYP39A1;CYP46A1;...
Th1 and Th2 cell differentiation -1.97 2.77e-3 80/92 (86.96%) NFKBIB;STAT5A;HLA-DOB;...
Mineral absorption -1.98 3.46e-3 48/60 (80%) FTH1;ATP1B2;SLC31A1;...
Metabolism of xenobiotics by cytochrome P450 -2.00 4.61e-3 49/77 (63.64%) UGT2B17;AKR1C1;CYP3A5;...
Osteoclast differentiation -2.12 0.00e+0 117/127 (92.13%) MAP2K6;FCGR3B;TYK2;...
Retinol metabolism -2.33 0.00e+0 41/68 (60.29%) RETSAT;ALDH1A3;RDH16;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 2.22uM 24H